I am a relatively new to the share register of Tissue Therapies...

I am a relatively new to the share register of Tissue Therapies being drawn to it by the opportunity their product represented, and so when I turned to the HC thread a few months ago on TIS to find out some more goss and whatever else about the company I was a little surprised at the sustained antagonism towards the management. There were various reasons but primarily it seemed that whenever targets were set they were apparently rarely met and also lack of news about progress. But yesterday a new event occurred for me which I haven’t seen previously in years of investing – on the release of their Annual Report the shares went up - actually just on 10% - perhaps the AR should have been labeled price sensitive. And it appears they went up because this report contained a host of information either not previously divulged or if it was it must not have been well understood. At last a lot of stuff was out in the open. So whilst I was initially pretty skeptical about all this management antagonism I think I might need to join the band here on HC and also raise my angst level about the disclosure levels of the company. I trust I shall not have to wait until next years’ AR to again find out so much about the company and what it is doing with its lead product. Incidentally if you ever want to see a good company model for disclosure have a look at SRX and also have a look at its share price – constantly going forward. I am sure the two – information and SP - are related.

Next year might TIS lift its game?

redgum